<?xml version="1.0" encoding="UTF-8"?>
<p>To address whether AAV vector vaccination induced broadly reactive antibodies with the ability to activate FcγR and thereby upregulate antiviral effector mechanisms, we used an assay that allows for separate analyses of all four murine FcγR (FcγRI, FcγRIIB, FcγRIII, and FcγRIV) (Fig 
 <xref rid="emmm201910938-fig-0003ev" ref-type="fig">EV3</xref>A; Van den Hoecke 
 <italic>et al</italic>, 
 <xref rid="emmm201910938-bib-0080" ref-type="ref">2017</xref>). AAV‐HA, AAV‐NP, and AAV‐cHA vaccines clearly more potently induced Cal/7/9 virus‐specific FcγR‐activating antibodies than WIV (Fig 
 <xref rid="emmm201910938-fig-0004" ref-type="fig">4</xref>A). Moreover, only the AAV‐vectored vaccines but not WIV induced FcγR‐activating antibodies against a heterologous virus strain, i.e., PR8, although at lower levels (Fig 
 <xref rid="emmm201910938-fig-0004" ref-type="fig">4</xref>B). Notably, AAV‐HA, AAV‐cHA, and WIV total PR8 antibody titers were not predictive for FcγR antibody titers (Fig 
 <xref rid="emmm201910938-fig-0003ev" ref-type="fig">EV3</xref>B). Interestingly, AAV‐NP sera induced strong FcγR‐activating antibody responses against both viruses (Fig 
 <xref rid="emmm201910938-fig-0004" ref-type="fig">4</xref>A and B).
</p>
